| 26.57 -0.94 (-3.42%) | 12-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 61.8 | 1-year : | 83.51 |
| Resists | First : | 52.91 | Second : | 71.5 |
| Pivot price | 28.56 |
|||
| Supports | First : | 22.85 | Second : | 19.01 |
| MAs | MA(5) : | 27.48 |
MA(20) : | 28.72 |
| MA(100) : | 30.48  |
MA(250) : | 0 | |
| MACD | MACD : | -5.4 |
Signal : | -5.5 |
| %K %D | K(14,3) : | 32.2 |
D(3) : | 37 |
| RSI | RSI(14): 32.1 |
|||
| 52-week | High : | 71.5 | Low : | 7.76 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ QURE ] has closed above bottom band by 15.3%. Bollinger Bands are 73.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 26.91 - 27.13 | 27.13 - 27.28 |
| Low: | 25.8 - 26.05 | 26.05 - 26.21 |
| Close: | 26.25 - 26.63 | 26.63 - 26.88 |
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Mon, 17 Nov 2025
Wall Street Has a Positive Outlook on uniQure N.V. (QURE) Despite Challenges From The FDA - Finviz
Sat, 15 Nov 2025
uniQure N.V. (NASDAQ:QURE) Analysts Just Slashed Next Year's Revenue Estimates By 26% - Yahoo Finance
Thu, 13 Nov 2025
Analysts Have Lowered Expectations For uniQure N.V. (NASDAQ:QURE) After Its Latest Results - Yahoo Finance
Wed, 12 Nov 2025
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm - GlobeNewswire
Mon, 10 Nov 2025
uniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 62 (M) |
| Held by Insiders | 4.591e+007 (%) |
| Held by Institutions | 5.3 (%) |
| Shares Short | 7,570 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.5437e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 329.7 % |
| Return on Equity (ttm) | -13.9 % |
| Qtrly Rev. Growth | 1.575e+007 % |
| Gross Profit (p.s.) | 116.6 |
| Sales Per Share | -311.84 |
| EBITDA (p.s.) | -2.32358e+008 |
| Qtrly Earnings Growth | -4.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -153 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.09 |
| Price to Cash Flow | 3.82 |
| Dividend | 0 |
| Forward Dividend | 8.39e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|